Hans Biomed한스바이오메드
042520 · KOSDAQ · ₩042520 · 한스바이오메드
₩17,880▲ ₩770 (4.50%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 59.2% | 57.4% | 63.8% | 57.8% | 61.4% | 49.5% |
| Operating margin | −18.5% | −28.8% | 0.8% | −5.3% | 1.7% | −33.5% |
| Net margin | −22.5% | −34.9% | −8.9% | −29.5% | 8.3% | −30.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +23.1% | +10.7% | +4.0% | +4.8% | +26.0% | — |
| Operating income growth | +21.2% | −4,238.5% | +115.1% | −421.4% | +106.5% | — |
| Net income growth | +20.7% | −333.9% | +68.7% | −474.9% | +133.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −46.1% | −62.3% | −12.5% | −48.6% | 13.6% | −41.1% |
| Return on assets | −21.2% | −25.9% | −6.4% | −19.0% | 3.8% | −17.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 100.0% | 273.0% | 81.3% | 145.0% | 177.5% | 172.0% |
| Net debt to equity | 30.2% | 97.8% | 44.5% | 64.9% | 84.3% | 60.8% |
| Current ratio | 124.2% | 69.2% | 99.2% | 77.2% | 73.0% | 83.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Hans Biomed / 한스바이오메드 / 042520 / KRX:042520
Source: KRX statistical information